Unknown

Dataset Information

0

Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma.

ABSTRACT:

SUBMITTER: Weinhold N 

PROVIDER: S-EPMC4815741 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma.
| S-EPMC7827173 | biostudies-literature
Unknown OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus.
| S-EPMC6944273 | biostudies-literature
Unknown ARNT/HIF-1β links high-risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma.
| S-EPMC6089175 | biostudies-literature
Unknown Chromosome 1q21 Aberrations Are Poor Prognostic Factors for Newly Diagnosed Multiple Myeloma Patients.
| S-EPMC11484708 | biostudies-literature
Unknown The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain.
| S-EPMC9019371 | biostudies-literature
Unknown Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma.
| S-EPMC8729045 | biostudies-literature
Unknown A novel human multiple myeloma cell line with a 1q21 gain genetic abnormality and CKS1B overexpression.
| S-EPMC9929770 | biostudies-literature
Unknown Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors.
| S-EPMC3678755 | biostudies-literature
Unknown Selective Enhancer Gain-of-Function Deregulates MYC Expression in Multiple Myeloma.
| S-EPMC11649448 | biostudies-literature
Unknown An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification.
| S-EPMC3257015 | biostudies-literature